Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute myeloid leukemia
Biotech
Syndax stock slips after AML drug hits midstage trial goal
The treatment’s overall response rate was 47% in the phase 2 portion of the trial, down from 63% in the phase 1 part.
Darren Incorvaia
Nov 12, 2024 2:00pm
Novartis' $2.9B MorphoSys bet stumbles as safety delays filing
Oct 29, 2024 6:16am
Shattuck axes CD47 program, cuts 40% of staff over weak data
Oct 1, 2024 8:22am
FDA sinks Actinium's radiotherapy blood cancer filing plans
Aug 5, 2024 8:12am
GlycoMimetics fails phase 3 blood cancer trial, sinking stock
May 6, 2024 8:11am
Nkarta's blood cancer CAR stalls again, driving deprioritization
Mar 22, 2024 9:11am
